SISI Research | Milton Maxwell

SISI

Shineco, Inc.

0.3750

+0.1510+67.4%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

337.73K

P/E (TTM)

Basic EPS (TTM)

-6802.27

Dividend Yield

Recent Filings

8-K

Nasdaq delisting finalized

10/8/25Oct 8, 2025

Shineco's common stock trading on Nasdaq was suspended October 7, 2025, after the Listing Council affirmed delisting on October 1 for failing the Bid Price Rule. Despite appeals to the SEC, court filings in New York and D.C. Circuit— all denied—trading halted. Company eyes options. No guarantees on relisting.

8-K

Nasdaq delisting stayed

7/31/25Jul 31, 2025

Shineco's Nasdaq delisting appeal failed at the Panel on July 25, 2025, with trading suspension set for July 29—but the Listing Council stayed it pending review, keeping shares listed. The company and two shareholders sued Nasdaq for contract breaches in New York federal court on July 28, withdrawing the TRO after the stay. Operations unaffected. No assurance of final listing retention.

8-K

Closes $13.5M share sale

7/9/25Jul 9, 2025

Shineco closed its previously announced sale of 18 million shares to non-U.S. investors at $0.75 each on July 2, 2025, netting $13.5 million gross before expenses. This unregistered equity raise bolsters the balance sheet amid Nasdaq listing pressures. Cash influx secured.

8-K

Nasdaq delisting notice issued.

6/23/25Jun 23, 2025

Shineco received a Nasdaq delisting notice on June 16, 2025, for failing the minimum $1 bid price rule, with no compliance period due to a prior reverse split. Trading suspends June 25 unless appealed by June 23—which Shineco plans to do, staying the suspension. Operations continue unaffected. Appeal buys time.

8-K

Shineco completes InfiniClone acquisition

6/23/25Jun 23, 2025

Shineco closed its acquisition of 51% of InfiniClone on June 18, 2025, paying the seller $19.9M cash plus 3.45M common shares. This deal makes InfiniClone a direct subsidiary of Shineco Life Science. Financials and pro formas to follow by amendment.

About

Shineco, Inc., through its subsidiaries, plants, processes, and distributes agricultural produce. The company also engages in the development, production, and distribution of diagnostic products and related medical devices; trading of fresh fruits; and processing, producing, and distribution of silk and silk fabrics, as well as other by-products. In addition, it operates a restaurant in Fuzhou. The company was formerly known as Beijing Tenet Jove Technological Development Co., Ltd. Shineco, Inc. was incorporated in 1997 and is based in Beijing, the People's Republic of China.

CEO

Ms. Jennifer Zhan

IPO

9/28/2016

Website

https://www.biosisi.com

Employees

119

Sector

Consumer Defensive

Industry

Farm Products